$1.4 Trillion Helium Crisis Creates Booming Opportunity For Investors
Did you know that helium is one of the most valuable resources on the planet? That's because almost every big tech company depends on it. And the world's helium supply is running dangerously low. That's bad news for big tech, but great news for helium investors.
And This One Company Just Made A Helium Discovery
Benjamin J. Hindson, insider at 10x Genomics
Benjamin J. Hindson Insider Alerts

Get notified the next time Benjamin J. Hindson buys or sells 10x Genomics stock. Enter your email address below to get our daily insider buying and selling report.

Benjamin J. Hindson Insider Information

Insider of 10x Genomics
Ben Hindson has served as Chief Scientific Officer and Director of 10x Genomics since its founding in 2012. Prior to 10x Genomics, he was Co-founder and Chief Scientific Officer of Quantalife, a privately-held life sciences company that developed and commercialized a droplet digital PCR platform, until its sale to Bio-Rad Laboratories in 2011. Before QuantaLife, Ben served in various positions of increasing responsibility at Lawrence Livermore National Laboratory in the Chemical and Biological Weapons Nonproliferation Program. He has published extensively in his field and holds numerous patents for assays and instrumentation. Ben earned his B.S. in Chemistry and his Ph.D in Chemistry from Deakin University, Australia.

What is Benjamin J. Hindson's net worth?

The estimated net worth of Benjamin J. Hindson is at least $6.85 million as of August 23rd, 2021. Dr. Hindson owns 47,117 shares of 10x Genomics stock worth more than $6,849,869 as of November 29th. This net worth estimate does not reflect any other assets that Dr. Hindson may own. Additionally, Dr. Hindson receives an annual salary of $614,970.00 as Insider at 10x Genomics. Learn More.

How old is Benjamin J. Hindson?

Dr. Hindson is currently 46 years old. There are 5 older executives and no younger executives at 10x Genomics. The oldest executive at 10x Genomics is Mr. Bradford J. Crutchfield, Chief Commercial Officer, who is 58 years old. Learn More.

What is Benjamin J. Hindson's salary?

As the Insider of 10x Genomics, Inc., Dr. Hindson earns $614,970.00 per year. The highest earning executive at 10x Genomics is Dr. Serge Saxonov Ph.D., Co-Founder, CEO & Director, who commands a salary of $654,990.00 per year.

How do I contact Benjamin J. Hindson?

The corporate mailing address for Dr. Hindson and other 10x Genomics executives is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. 10x Genomics can also be reached via email at [email protected]

Has Benjamin J. Hindson been buying or selling shares of 10x Genomics?

Over the course of the past ninety days, Benjamin J. Hindson has sold $12,849,377.00 of 10x Genomics stock. Most recently, Benjamin J. Hindson sold 351 shares of the business's stock in a transaction on Monday, November 22nd. The shares were sold at an average price of $148.38, for a transaction totalling $52,081.38.

Who are 10x Genomics' active insiders?

10x Genomics' insider roster includes Bradford Crutchfield (Insider), Benjamin Hindson (Insider), Sridhar Kosaraju (Director), Justin McAnear (CFO), Serge Saxonov (CEO), and John Stuelpnagel (Director).

Are insiders buying or selling shares of 10x Genomics?

During the last year, insiders at the sold shares 67 times. They sold a total of 762,236 shares worth more than $128,950,934.97. The most recent insider tranaction occured on November, 22nd when CFO Justin J Mcanear sold 281 shares worth more than $41,694.78. Insiders at 10x Genomics own 11.6 % of the company.

Information on this page was last updated on 11/22/2021.

Benjamin J. Hindson Insider Trading History at 10x Genomics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/22/2021Sell351$148.38$52,081.38View SEC Filing Icon  
11/1/2021Sell41,666$163.58$6,815,724.28View SEC Filing Icon  
10/1/2021Sell41,666$143.56$5,981,570.96View SEC Filing Icon  
9/1/2021Sell41,666$177.50$7,395,715.00View SEC Filing Icon  
8/23/2021Sell337$161.85$54,543.4547,117View SEC Filing Icon  
5/3/2021Sell41,666$191.84$7,993,205.4460,716View SEC Filing Icon  
4/1/2021Sell41,666$184.54$7,689,043.6478,302View SEC Filing Icon  
2/1/2021Sell33,750$175.98$5,939,325.0069,686View SEC Filing Icon  
1/4/2021Sell33,750$139.93$4,722,637.50100,437View SEC Filing Icon  
12/1/2020Sell33,750$151.32$5,107,050.00101,250View SEC Filing Icon  
11/2/2020Sell21,062$136.38$2,872,435.5688,562View SEC Filing Icon  
9/1/2020Sell27,692$113.97$3,156,057.2495,192View SEC Filing Icon  
8/3/2020Sell33,750$99.34$3,352,725.00101,250View SEC Filing Icon  
7/1/2020Sell33,750$87.60$2,956,500.00101,250View SEC Filing Icon  
6/1/2020Sell33,750$79.85$2,694,937.50101,250View SEC Filing Icon  
5/1/2020Sell33,750$77.38$2,611,575.00101,250View SEC Filing Icon  
4/1/2020Sell33,750$58.12$1,961,550.00101,250View SEC Filing Icon  
3/6/2020Sell33,750$65.59$2,213,662.50101,250View SEC Filing Icon  
See Full Table

Benjamin J. Hindson Buying and Selling Activity at 10x Genomics

This chart shows Benjamin J Hindson's buying and selling at 10x Genomics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

10x Genomics Company Overview

10x Genomics logo
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Read More

Today's Range

Now: $145.38
Low: $140.38
High: $149.09

50 Day Range

MA: $157.72
Low: $142.29
High: $182.59

2 Week Range

Now: $145.38
Low: $128.15
High: $208.99

Volume

36,388 shs

Average Volume

720,963 shs

Market Capitalization

$16.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39
All Electric Commitment From GM, Volkswagen, Could Put Lithium Stock In A Supercycle
More automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...
Look At This Under-The-Radar Lithium Company